AR and prostate cancer: Using a high-resolution ChIP-exo approach, we recently found that enzalutamide induces AR binding to the novel binding motif 5′-NCHKGNnndDCHDGN, stimulating the expression of several antagonist-responsive, cancer-relevant genes (e.g. CPEB4) in prostate cancer cells (16).